Chidamide Plus Nivolumab Shows Potential Frontline Role in Melanoma
Chidamide (HBI-8000) combined with nivolumab (Opdivo) showed improved efficacy and safety in metastatic melanoma patients compared to nivolumab alone, according to a phase 3 trial presented at ESMO Congress 2026. The trial reported a median PFS of 11.7 months for the combination vs 7.4 months for placebo, with a 41.4% vs 32.3% response rate. Grade 3+ adverse events were higher in the combination group (55% vs 18%).
How this was made
The 30-second read
Why it matters
First public disclosure of statistically significant PFS improvement, offering a new frontline option and potentially expanding Bristol Myers' oncology portfolio.
Market read
Positive trial data could drive short-term upside in BMS and influence broader oncology investment sentiment.
What to watch
Regulatory approval timeline and reimbursement uncertainty could temper price gains.
Background
The HBI-8000-303 trial presented at ESMO 2026 evaluates an oral HDAC inhibitor combined with Opdivo in untreated metastatic melanoma.
Market effects
May boost confidence in HDAC inhibitor combos across oncology sector.
US biotech investors likely to react; limited immediate impact elsewhere.
Potentially influences global melanoma treatment landscape.
Counterpoint
Data may not translate to commercial success if safety concerns or competition intensify.
Key entities
- CompanyBristol Myers Squibb
Manufacturer of nivolumab (Opdivo) and potential partner for the chidamide combo.
- DrugChidamide (HBI-8000)
Oral selective HDAC inhibitor under investigation.
